PD-L1 Expression Scoring: Noninterchangeable, Noninterpretable, Neither, or Both
Open Access
- 7 June 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 113 (12), 1613-1614
- https://doi.org/10.1093/jnci/djab109
Abstract
Niki Gavrielatou, MD, Saba Shafi, MD, Patricia Gaule, PhD, David L Rimm, MD-PhD; PD-L1 Expression Scoring: Non-Interchangeable, Non-Interpretable, Neither, or BKeywords
Funding Information
- Breast Cancer Research Foundation (20-198)
This publication has 7 references indexed in Scilit:
- PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast CancerJNCI Journal of the National Cancer Institute, 2021
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialThe Lancet, 2020
- Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancerLaboratory Investigation, 2020
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric CancerArchives of Pathology & Laboratory Medicine, 2019
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2018
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectJournal of Thoracic Oncology, 2018
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung CancerJAMA Oncology, 2017